Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population
- PMID: 20351623
- DOI: 10.1097/OLQ.0b013e3181cfcd8c
Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population
Abstract
Objective: To determine the prevalence and incidence of trichomoniasis, risk factors for infection, and the prevalence of metronidazole and tinidazole-resistant Trichomonas vaginalis (T. vaginalis) in female adolescents.
Methods: Nonpregnant, HIV-seronegative, sexually active females (13-19 years) visiting an inner city public primary care clinic were tested for T. vaginalis by wet mount and culture, and interviewed about risk-taking behavior every 6 months. Infected patients were treated with a 2 g oral dose of metronidazole. Isolates from positive T. vaginalis cultures were tested for in vitro resistance to metronidazole and tinidazole.
Results: Among 467 study participants, 67 (14.4%; 95% confidence interval, 11.3-17.5) were diagnosed with trichomoniasis at first T. vaginalis culture. Significant risk factors for T. vaginalis infection were having an older sex partner and concurrent Neisseria gonorrhoeae infection. The incidence was 22.1 cases per 100 person-years. Among 42 participants who had a prevalent infection and returned for followup, 13 (31.0%) had at least 1 more episode of trichomoniasis. Resistance testing was completed for 78 isolates: 37 at first visit and 41 during follow-up. One (2.7%; 95% confidence interval, 0.07-14.2) of the 37 first-visit isolates was moderately resistant to metronidazole (minimal lethal concentration = 200 microg/mL). Of the 41 follow-up visit isolates, 1 was moderately resistant to metronidazole and 2 had borderline resistance (minimal lethal concentration = 50 microg/mL). The prevalence of tinidazole resistance was 0% (0.0%-9.5%).
Conclusion: The study population had high prevalence and incidence of trichomoniasis. The prevalence of antibiotic-resistant T. vaginalis among female adolescents was low.
Similar articles
-
Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention.Clin Infect Dis. 2007 Jan 1;44(1):13-22. doi: 10.1086/511144. Epub 2006 Nov 27. Clin Infect Dis. 2007. PMID: 17143809
-
Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women.J Infect Dis. 2005 Dec 15;192(12):2039-44. doi: 10.1086/498217. Epub 2005 Nov 8. J Infect Dis. 2005. PMID: 16288365
-
Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic.J Reprod Med. 2001 Jun;46(6):545-9. J Reprod Med. 2001. PMID: 11441678
-
Trichomoniasis and its treatment.Expert Rev Anti Infect Ther. 2006 Feb;4(1):125-35. doi: 10.1586/14787210.4.1.125. Expert Rev Anti Infect Ther. 2006. PMID: 16441214 Review.
-
Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations.Expert Rev Anti Infect Ther. 2014 Jun;12(6):673-85. doi: 10.1586/14787210.2014.887440. Epub 2014 Feb 20. Expert Rev Anti Infect Ther. 2014. PMID: 24555561 Review.
Cited by
-
Ginger (Zingiber officinale) induces apoptosis in Trichomonas vaginalis in vitro.Int J Reprod Biomed. 2016 Nov;14(11):691-698. Int J Reprod Biomed. 2016. PMID: 27981254 Free PMC article.
-
Epidemiology and treatment of trichomoniasis.Curr Infect Dis Rep. 2015 Jun;17(6):484. doi: 10.1007/s11908-015-0484-7. Curr Infect Dis Rep. 2015. PMID: 25925796 Free PMC article.
-
Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.Clin Infect Dis. 2022 Apr 13;74(Suppl_2):S152-S161. doi: 10.1093/cid/ciac030. Clin Infect Dis. 2022. PMID: 35416973 Free PMC article. Clinical Trial.
-
Screening for nonviral sexually transmitted infections in adolescents and young adults.Pediatrics. 2014 Jul;134(1):e302-11. doi: 10.1542/peds.2014-1024. Pediatrics. 2014. PMID: 24982099 Free PMC article.
-
Trichomoniasis - are we giving the deserved attention to the most common non-viral sexually transmitted disease worldwide?Microb Cell. 2016 Jun 27;3(9):404-419. doi: 10.15698/mic2016.09.526. Microb Cell. 2016. PMID: 28357378 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical